NCT04230265View on ClinicalTrials.gov

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

May 31, 2025

Study Completion Date

September 30, 2025

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Cyclophosphamide (Non-IMP)

Intravenous infusion over 3 days

DRUG

Fludarabine (Non-IMP)

Intravenous infusion over 3 days

DRUG

TM123 (IMP)

Intravenous Infusion for 20 days

DRUG

UniCAR02-T (IMP)

Intravenous infusion of single dose

Trial Locations (10)

3015

Erasmus University Medical Center, Rotterdam

9713

Universitair Medisch Centrum Groningen, Groningen

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

35032

Philipps-Universität Marburg, Marburg

52074

Uniklinik RWTH Aachen, Aachen

81377

Klinikum der Universität München, Munich

89081

Universitätsklinikum Ulm, Ulm

97080

Universitätsklinikum Würzburg, Würzburg

01307

Universitätsklinikum Dresden, Dresden

04103

Universitätsklinikum Leipzig, Leipzig

All Listed Sponsors
collaborator

PHARMALOG Institut für klinische Forschung GmbH

UNKNOWN

lead

AvenCell Europe GmbH

INDUSTRY